Healthcare Industry News: GPC Biotech
News Release - April 10, 2009
Pfizer's Oncology Business Unit Appoints Vice President of Medical AffairsNEW YORK--(HSMN NewsFeed)--Pfizer Inc announced today the appointment of Martine J. George, M.D., M.Sc, to Vice President of Medical Affairs for its Oncology Business Unit. Dr. George will be responsible for managing external relationships with cancer agencies, organizations and specialists around the world.
“We are delighted that Dr. George – with her impressive record as a leader in global pharmaceutical organizations – will be joining Pfizer’s Oncology Business Unit and look forward to her contributions in advancing science needed to bring innovative medicines to patients,” said Mace L. Rothenberg, M.D., senior vice president, Clinical Development and Medical Affairs for the Oncology Business Unit.
Dr. George possesses 20 years of experience in leading pharmaceutical organizations with expertise in medical affairs, clinical research and regulatory affairs. Most recently, she held the position of Senior Vice President of Drug Development and Chief Medical Officer at GPC Biotech, Inc. where she was responsible for the strategy and development activities for satraplatin and all early development compounds.
Her previous experience includes serving as Senior Vice President and Head of Oncology for Johnson & Johnson and as Vice President of Clinical Affairs at Ortho Biotech, Inc. Additionally, she has led the medical affairs group at Rhone-Poulenc Rorer (Sanofi-Aventis), worldwide clinical research and regulatory affairs at Gencell, and clinical research and development at Sandoz Pharmaceuticals Corporation (Novartis). Prior to joining industry she held an academic position at Institute Gustave Roussy, Villejuif, France for several years.
Dr. George received her M.Sc in Pharmacology from Montreal University in 1973, her M.D. from Paris University in 1975, and is board certified in Medical Oncology.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.